Press Release

CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com

Corcept Announces Revised Reporting Dates for One of Its Three Phase III Clinical Trials

Menlo Park, Calif., (September 26, 2005) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that, due to a slower than anticipated pace of patient enrollment, it has revised the date by which it expects to report the results of one of the three Phase III trials it is conducting to evaluate CORLUX® for the treatment of the psychotic features of Psychotic Major Depression (PMD). The Company now expects to report results from its 06 trial in the second half of 2006. It had previously reported that it would report the results from this trial by the end of the first half of 2006. Corcept expects to report the results of its other two Phase III trials in the time frame previously provided.

"The enrollment in our 07 trial is such that we continue to expect to report results by the end of the first half of 2006", said Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept, "We also continue to anticipate having initial results from our 09 study, which is being conducted in Europe, available by the end of 2006."

Dr. Belanoff further stated, "We believe that our cash and marketable securities, which was $36.7 million at June 30, 2005, will enable us to complete, as currently planned, the clinical development of our lead product candidate, CORLUX, for the treatment of the psychotic features of PMD."

ABOUT CORCEPT THERAPEUTICS INCORPORATED

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is currently in Phase III clinical trials for the treatment of the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. For additional information about the company, please visit www.corcept.com.

Statements made in this news release, other than statements of historical fact, are forward-looking statements, including, for example, statements relating to our clinical development programs and the expected timing and results of our clinical trials, our spending pace, and our expected financial results. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. For example, there can be no assurances with respect to the commencement, cost, rate of spending, completion or success of clinical trials; there can be no assurances with respect to the regulatory process or regulatory approvals. These and other risk factors are set forth in the Company's SEC filings, all of which are available from our website (www.corcept.com) or from the SEC's website (www.sec.gov). We disclaim any intention or duty to update any forward-looking statement made in this news release.